ZB-R-55 is an orally active and selective dual-mode RIPK1 inhibitor with RIPK1 IC 50 values of 5.7 nM. ZB-R-55 occupies both the allosteric and ATP binding sites of RIPK1 . ZB-R-55 inhibits necroptosis in cancer cells. ZB-R-55 can be used for the research of systemic inflammatory response syndrome and sepsis.
Products | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Bacterial Infection | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > RIP kinase | Products > Signaling Pathways > Necroptosis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.